



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 7/06, A61K 39/21	A1	(11) International Publication Number: WO 99/41360 (43) International Publication Date: 19 August 1999 (19.08.99)
(21) International Application Number: PCT/US99/03217 (22) International Filing Date: 12 February 1999 (12.02.99) (30) Priority Data: 60/074,646 13 February 1998 (13.02.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/074,646 (CIP) Filed on 13 February 1998 (13.02.98) (71)(72) Applicant and Inventor: RIOS, Adan [US/US]; 4007 Shallow Pond Court, Sugar Land, TX 77479 (US). (74) Agent: WILSON, Mark, B.; Arnold White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHOD FOR THE DEVELOPMENT OF AN HIV VACCINE		
(57) Abstract Human immunodeficiency virus (HIV) comprising reverse transcriptase inactivated by photoinactivation used to evoke an immune response. The immune response may protect an individual from challenges with live virus. Alternatively, the inactivated HIV particles may be used to augment the immune response to HIV in an infected individual.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DESCRIPTION

METHOD FOR THE DEVELOPMENT OF AN HIV VACCINE

5 1.0 BACKGROUND OF THE INVENTION

This application is a continuation-in-part application and claims priority to prior pending provisional U.S.patent application No. 60/074,646, filed on February 13, 1998.

10 1.1 FIELD OF THE INVENTION

The present invention relates generally to the fields of disease treatment and prevention. More particularly, it concerns HIV particles with inactivated reverse transcriptase and the use of such particles to elicit an effective immunological response to HIV. This immune response will provide protection from an HIV
15 challenge and/or will assist the HIV-infected individual in controlling the replication of the virus.

1.2 DESCRIPTION OF RELATED ART

1.2.1 HUMAN IMMUNODEFICIENCY VIRUS

20 Human Immunodeficiency Virus-1 (HIV-1) infection has been reported throughout the world in both developed and developing countries. HIV-2 infection is found predominately in West Africa, Portugal, and Brazil. It is estimated that as of 1990 there were between 800,000 and 1.3 million individuals in the United States that were infected with HIV. An important obstacle to developing a vaccine against HIV
25 is that the mechanism of immunity to HIV infection is ill-understood. Not all of those infected individuals will develop acquired immunodeficiency syndrome (AIDS). Indeed recent reports have suggested that there may be certain individuals that are resistant to HIV-1 infection.

30 The HIV viruses are members of the Retroviridae family and, more particularly, are classified within the Lentivirinae subfamily. Like nearly all other viruses, the replication cycles of members of the Retroviridae family, commonly

known as the retroviruses, include attachment to specific cell receptors, entry into cells, synthesis of proteins and nucleic acids, assembly of progeny virus particles (virions), and release of progeny viruses from the cells. A unique aspect of retrovirus replication is the conversion of the single-stranded RNA genome into a double-stranded DNA molecule that must integrate into the genome of the host cell prior to the synthesis of viral proteins and nucleic acids.

Retrovirus virions are enveloped and contain two copies of the genome. The conversion of the genomic RNA into DNA is provided by the viral protein reverse transcriptase (RT). This protein is bound to the RNA genome within the virion, and its enzymatic conversion of the genome to DNA is believed to take place after viral entry into the host cell. However, recent evidence suggests that the conversion process may initiate in the virion particles themselves, known as endogenous reverse transcription (ERT), and that ERT may be important in increasing the infectivity of the virus in sexual transmission (Zhang *et al.*, 1993, 1996).

Because of the requirement for reverse transcription in the viral replication cycle, compounds that interfere with RT activity have been utilized as anti-HIV therapeutic agents. Many of these compounds, including 3'-azido-2', 3'-dideoxythymidine (AZT), are nucleoside analogs that, upon activation by host cell kinases, are competitive inhibitors of reverse transcriptase (Furman *et al.*, 1986). Other anti-RT compounds are nonnucleoside inhibitors (NNI), hydrophobic compounds that do not require cellular modification for antiviral activity. Examples of such compounds include nevirapine (Grob *et al.*, 1992; Merluzzi *et al.*, 1990), the pyridinones (Carroll *et al.*, 1993; Goldman *et al.*, 1991), and the carboxanilides (Bader *et al.*, 1991; Balzarini *et al.*, 1995, 1996). The nevirapine analog 9-azido-5,6-dihydro-11-ethyl-6-methyl-11*H*-pyrido[2,3-*b*][1,5]benzodiazepin-5-one (9-AN) and the carboxanilide analog *N*-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-furanocarbothiamide (UC781TM) have been shown to be potent inhibitors of RT. In respect of the 9-AN, the exposure of a mixture of this compound and RT to UV-irradiation has been particularly effective in inhibiting RT. From the series of carboxanilides compounds, UC781TM has been found to be particularly effective (Barnard *et al.*, 1997). The addition of a photoreactive label to UC781TM

should increase further its ability to inactivate HIV RT, when a mixture of UC781™ and RT is exposed to UV-irradiation. The irradiation of a mixture of a photolabeled NNI of RT and RT is a type of photoinactivation.

The binding affinity and inhibitory effect of UC781™ is so high that the compound was able to eliminate HIV infectivity following short exposure of the isolated virus to UC781™ without the need for photoinactivation (Borkow *et al.*, 1997). Further, this compound was shown to inhibit ERT in HIV virions and, when provided to HIV infected cells, caused the production of noninfectious nascent virus (Borkow *et al.*, 1997). Therefore, it appears that UC781™ is a particularly powerful inactivator of HIV. Although UC781™ has been proposed for use in retrovirucidal formulations (Borkow *et al.*, 1997), use as a photoinactivator of HIV for the purpose of producing a vaccine is absent from the prior art.

1.2.2 IMMUNE RESPONSE TO HIV

The immune response to HIV is composed of an initial cell mediated immune response followed by the subsequent development of neutralizing antibodies. Within weeks of infection, virus titers in the blood fall coincident with the induction of anti-HIV cellular and humoral immune responses. The fall in viremia correlates well with the appearance of anti-HIV major histocompatibility complex (MHC) class I-restricted CD8⁺ cytotoxic T cells (Haynes *et al.*, 1996). Recent evidence has shown a strong correlation of anti-HIV CD4⁺ T cell responses and reduced viral loads (Rosenberg *et al.*, 1997). Therefore, the presentation of HIV antigens in the context of MHC class II molecules to CD4⁺ T cells may be the key aspect of the control of the HIV infection.

Rosenberg *et al.* (1997) suggest that in HIV-1 infection, HIV-specific CD4⁺ cells may be selectively eliminated. This may be due to the activation of these cells during high-level viremia, increasing their susceptibility to infection (Weissman *et al.*, 1996; Stanley *et al.*, 1996), or may be due to activation induced cell death during primary infection (Abbas, 1996). Nonetheless, increasing the virus-specific CD4⁺ T cell response without infecting, or destroying, the responding cells may be an effective means of controlling viral loads. Therefore, some existing HIV vaccines

may be ineffective because they do not provide presentation of HIV peptides in the context of MHC class II by antigen presenting cells.

1.2.3 HIV VACCINES

Historically, viral vaccines have been enormously successful in the prevention of infection by a particular virus. Therefore, when HIV was first isolated, there was a great amount of optimism that an HIV vaccine would be developed quickly. However, this optimism quickly faded because a number of unforeseen problems emerged. A discussion of the problems that an HIV vaccine must overcome is provided within Stott and Schild (1996) and is incorporated herein by reference.

First, HIV is a retrovirus, thus, during its growth cycle, proviral DNA is integrated in the host genome. In this form the virus is effectively protected from the immune response of the host and this feature of the virus suggests that effective vaccination must ideally prevent the initial virus-cell interaction following transmission. Few, if any, of the currently available successful viral vaccines against other infections achieve this level of protection. Secondly, HIV specifically targets and destroys T-helper lymphocytes, which form an essential component of the immune response. Thirdly, the virus is capable of extremely rapid antigenic variation which permits escape of the virus from immune responses. Fourthly, the majority of infections are acquired sexually via the genital or rectal mucosae, and infections of this route are generally considered difficult to prevent by vaccination. Finally, infection may be transmitted by virus-infected cells in which the proviral DNA is integrated and viral antigens are not expressed. Such a cell would not be recognized by immune responses to viral proteins and would therefore pass undetected. Few data are available to indicate how significant this mode of transmission is in the overall epidemiology of HIV-1. Nevertheless, it represents a potential route and one which some authorities believe cannot be blocked by vaccination (Sabin, 1992).

Types of HIV vaccines include inactivated virus vaccines, live attenuated virus vaccines, virus subunit vaccines, synthetic particle vaccines, and naked DNA vaccines and are reviewed in Stott and Schild (1996), Schultz (1996), and Johnston (1997). Several of these vaccines are already in human trials.

The first evidence that vaccination against immunodeficiency viruses was feasible came from early experiments using simple inactivated virus prevented the onset of disease when vaccinated animals were subsequently challenged (Desrosiers *et al.*, 1989; Sutjipto *et al.*, 1990). These results were confirmed and extended by Murphey-Corb *et al.* (1989) who showed that most animals immunized with formalin-inactivated virus were protected against infection with SIV. Similar results were subsequently obtained by several laboratories using virus-infected cells (Stott *et al.*, 1990) or partially purified virus, inactivated by aldehydes (Putkonen *et al.*, 1991, 1992; Johnson *et al.*, 1992a; Le Grand *et al.*, 1992), β -propiolactone (Stott *et al.*, 1990) detergent (Osterhaus *et al.*, 1992) or psoralin and UV light (Carlson *et al.*, 1990). Several different isolates of SIV or infectious molecular clones derived from them were used to prepare the vaccine and challenge viruses. A wide variety of adjuvants were also employed. On every occasion vaccinated macaques were protected against infection by intravenous challenge of between 10-50 MID₅₀ (50% monkey infectious doses). Infections virus could not be recovered from the blood or tissues of the protected animals even when they were followed for prolonged periods of over 1 year. Even more impressive was the failure to detect proviral DNA in the lymphocytes of protected animals, indicating that there had been no integration of the challenge virus (Stott *et al.*, 1990; Johnson *et al.*, 1992a). It was thus clear that inactivated virus vaccines induced a powerful protective response in macaques. Unfortunately, the protection induced by inactivated SIV in macaques was not reproduced in chimpanzees vaccinated with inactivated HIV and challenged with HIV-1 (Warren and Doltshahi, 1993).

1.2.4 PHOTOINACTIVATION OF HIV

Methods of photoinactivation of HIV are known in the art and have been the subject of at least three patents. U.S. Patent 5,041,078 describes the use of sapphyrins in the photodynamic inactivation of viruses, including HIV. U.S. Patents 5,516,629 and 5,593,823 describe the use of psoralens and ultra violet light to inactivate HIV. U.S. Patents 5,516,629 is incorporated herein by reference. Psoralens are naturally occurring compounds which have been used therapeutically for millennia in Asia and

Africa. A psoralen binds to nucleic acid double helices by intercalation between base pairs. Upon absorption of UVA photons, the psoralen excited state has been shown to react with a thymine or uracil double bond and covalently attach to both strands of a nucleic acid helix. The crosslinking reaction is specific for a thymine (DNA) or uracil (RNA) base and will proceed only if the psoralen is intercalated in a site containing thymine or uracil. The initial photoadduct can absorb a second UVA photon and react with a second thymine or uracil on the opposing strand of the double helix to crosslink the two strands of the double helix.

Lethal damage to a cell or virus occurs when a psoralen intercalated into a nucleic acid duplex in sites containing two thymines (or uracils) on opposing strands sequentially absorb 2 UVA photons. This is an inefficient process because two low probability events are required, the localization of the psoralen into sites with two thymines (or uracils) present and its sequential absorption of 2 UVA photons.

Attempts to inactivate viruses using photosensitizers and light have also been developed using some non-psoralen photosensitizers. The photosensitizers that have been employed are typically dyes. Examples include dihematoporphyrin ether (DHE), Merocyanine 540 (MC540) and methylene blue.

Carlson *et al.* (1990) has shown that a psoralen-inactivated whole SIV (the Simian counterpart of HIV) vaccine can protect against low challenge doses of SIV and prevent early death in those monkeys that do become infected, suggesting that inactivated HIV may be an effective vaccine in humans. However, because photoinactivation using psoralens is dependent on two rare events, a more efficient method of inactivation is preferable to decrease the likelihood of live virus within a sample. Furthermore, these methods alter the antigenic conformation of HIV affecting the production of an effective immunological response.

1.3 DEFICIENCIES IN THE PRIOR ART

Due to previous successes in preventing viral diseases using subunit, live-attenuated viral, and inactivated viral vaccines, the scientific community was initially optimistic that a vaccine would be developed to prevent the spread of HIV. However,

early optimism soon diminished because of repeated failures in the development of an effective vaccine.

Subunit vaccines, although extremely safe, are limited in the breadth of antigens that are presented to the immune system because only one or a few of the viral proteins are utilized in the vaccine. This may limit the likelihood of cross protection between clades of HIV. Also, the production of subunit vaccines requires the molecular manipulation of the viral proteins into cloning or expression vectors, perhaps leading to increased production time and costs.

Live-attenuated HIV vaccines may also require molecular manipulations in their production, although spontaneous attenuated viruses may occur naturally. Attenuated HIV vaccines have included deletions in the *nef* region of the virus. Mutant-*nef* SIV vaccines showed initial promise in primates, however, it was quickly shown that these vaccines were capable of causing disease in newborn animals. Furthermore, recent evidence suggests that these vaccines are capable of causing full-blown AIDS in adult monkeys (Cohen, 1997). Therefore, the lack of an efficient understanding of HIV and its pathogenesis makes the use of attenuated viruses a risky endeavor.

Inactivated viral vaccines provide a larger complement of antigens that are presented to the immune system, and, therefore, provide a greater amount of protection from HIV and is more likely to provide protection across HIV clades. Furthermore, the inactivated viral vaccines do not require molecular manipulation of HIV and can be made to essentially any strain. Because inactivation of the virus is readily shown in *in vitro* and animal models, the inactivated HIV vaccines are able to be tested in a timely manner to determine the effectiveness of inactivation. Attenuated viruses may take years to determine the effectiveness of the vaccine.

To be safe to administer to humans, efficient methods of inactivation of HIV are required for vaccine production. Methods known for the inactivation include the use of aldehydes, β -propiolactone, psoralin and UV light, and others including detergents. Many of these methods alter the conformation of the virus thereby altering the specificity of the immune response to the virus. Photoinactivation of HIV using psoralin and UV light does not alter the conformation of the virus, but it is an

inefficient method of inactivation. Therefore, more efficient methods of inactivation that do not affect the conformation of the virus would be ideal for use in the production of an HIV vaccine.

5 2.0 SUMMARY

The prior art is devoid of HIV vaccines created using an efficient method of inactivating HIV without causing deformation of the viral particle. The vaccine of the present invention is produced using efficient methods of inactivation that do not alter the conformation of the virus to the same extent as other inactivation methods.
10 Therefore, the vaccine of the present invention mimics infectious HIV particles but does not cause infection (*i.e.*, establishment of a perpetuation of HIV within the recipient host due to incorporation of HIV into the genome of cells within that host).

The use of an azido dipyrrocliazepinone and an azido thiocarboxanilide (azido UC781™), azido-labeled compounds shown to bind and inactivate RT, permits the
15 generation of non-infectious particles of HIV by inactivating the HIV RT upon exposure of infectious particles to either compound followed by irradiation with ultraviolet light. The effective inactivation of HIV RT by the methods described herein allows the production of non-infectious particles of HIV. These non-infectious particles of HIV have the capacity of eliciting an effective cell mediated and antibody
20 mediated immune response which is protective against infection by HIV. The inactivated HIV particles of the present invention preserve the antigenic composition of infectious wild-type HIV particles and thereby facilitate the dendritic cell-mediated processing and presentation of HIV particle-derived antigens to T cells.

The application of this methodology to different strains of HIV may allow the
25 production of a polyvalent vaccine (NIIPAV or NON-Infectious Immunogenic Polyvalent AIDS Vaccine). The inactivated HIV particles of the present invention upon binding to CD4 receptors will expose epitopes which may elicit broad immunogenic responses capable of inhibiting the infectivity of diverse types of HIV from different clades. Thus the exposure of the immune system to a single type of
30 inactivated particle of the present invention may protect against infection by multiple types of HIV.

One aspect of the present invention is a composition comprising an HIV particle in which the RT is inactivated. The composition may further comprise a pharmaceutically-acceptable excipient. The present invention contemplates that the HIV particle may be any type, subtype or isotype of HIV. In a preferred embodiment, the HIV particle is a wild type HIV particle. In one embodiment the HIV particle is HIV 1. The HIV 1 particle may be Group M or Group O. In different embodiments the Group M HIV 1 may be clade A, clade B, clade C, clade D, clade E, clade F, clade G, clade H, or clade I. In a preferred embodiment of the invention, the Group M particle is a clade B particle.

In one embodiment the RT is inactivated by one or more compounds that binds the RT and then irradiating bound RT with UV light. In a preferred embodiment the UV light is that emitted by a GE 275 W sun lamp. However, it is contemplated that any light that causes the reaction of the compound with RT may be used. In one embodiment of the compound that binds to RT is an azido labeled compound. Essentially any azido-labeled compound that binds to HIV RT and can penetrate the HIV particle so as to associate with RT may be used. In a preferred embodiment the azido-labeled compound is azido dipyrroliadiazepinone or azido-UC781TM. In other embodiments the azido-labeled compound is the azido derivative of 9-AN, UC38, UC84, UC10, UC82, UC040, HBY 097, calanolide A, or U-88204E. In one embodiment the inactivation of RT comprises contacting said HIV particle with an effective amount of the azido labeled compound.

Another aspect of the present invention is a method of invoking an immune response in an animal by administering a composition comprising a pharmaceutically-acceptable excipient and an HIV particle in which the RT is inactivated. The immune response may be a humoral response, a cellular response or both a humoral and cellular response. The cellular response may be a CD8⁺ T cell response, a CD4⁺ T cell, or both a CD8⁺ T cell and a CD4⁺ T cell response.

The animal in which the immune response is invoked may be a mammal. In preferred embodiments the mammal may be a human, a PBL-SCID mouse, or a SCID-hu mouse. The animal in which the immune response is invoked may be either HIV positive or HIV negative.

Another aspect of the present invention is a method of delaying the onset of AIDS in an animal exposed to infectious HIV by administering to the animal an inoculation of a pharmaceutically acceptable excipient and an HIV particle in which the RT is inactivated. The animal may be a mammal and in preferred embodiments the mammal is a human, a PBL-SCID mouse, or a SCID-hu mouse. The animal may be either HIV negative or HIV positive at the time of the administration of the inoculation.

Another aspect of the present invention is a method of making an HIV particle containing an inactivated RT comprising contacting a compound capable of inactivating RT with an HIV particle such that the compound binds to the RT and then irradiating the HIV particle. In one embodiment the HIV particle is HIV 1. The HIV 1 particle may be Group M or Group O. In different embodiments the Group M HIV 1 may be clade A, clade B, clade C, clade D, clade E, clade F, clade G, clade H, or clade I. In a preferred embodiment of the invention, the Group M particle is a clade B particle.

In one embodiment of the compound capable of inactivating RT is an azido labeled compound. Essentially any azido-labeled compound that binds to HIV RT and can penetrate the HIV particle so as to associate with RT may be used. In preferred embodiments the azido-labeled compound is azido dipyrodiazepinona or azido-UC781TM. In other embodiments the azido-labeled compound is the azido derivative of 9-AN, UC38, UC84, UC10, UC82, UC040, HBY 097, calanolide A, or U-88204E.

Another aspect of the present invention is a method of preparing a composition comprising making an HIV particle containing an inactivated RT by contacting a compound capable of inactivating RT with an HIV particle such that the compound binds to the RT, irradiating the HIV particle, and then combining the HIV particle with the inactivated RT with a pharmaceutically acceptable excipient.

3.0 BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be

better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIG. 1. Simplified phylogenetic tree of HIV-1. Group M denotes the major group of HIV-1; group O refers to outliers or outgroup. Sequence data from the *env* gene C2V3 region of selective isolates of subtypes A through H were compared to construct the phylogenetic tree. A ninth subtype, I, has been reported recently but is not shown because the isolate was characterized using a different segment of the *env* gene. The horizontal branch lengths represent approximate relative genetic distances. (From Hu D J, Dondero TJ, Rayfield MA, *et al.*, The emerging genetic diversity of HIV: The importance of global surveillance for diagnostics, research, and prevention. JAMA 275:210, 1996.)

4.0 DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The present invention relates to a vaccine comprising RT-inactivated HIV for the purpose of eliciting a protective immune response in an animal. The present invention employs methods of inactivating RT. Further, the use of these inactivation methods for the purpose of producing a vaccine is novel.

There are well described methods for the isolation and culture of HIV. What is important to keep present in regard to the objectives of this invention is the fact that, using a methodology that inactivates the HIV reverse transcriptase, non-infectious particles of HIV are obtained which are capable of eliciting an effectively protective immune response. Thus, although it makes sense to describe the method using specific strains of HIV and specific types of cells for the culture and testing of the lack of infectiousness of the generated particles, it should be kept in mind that this method may apply to different strains of HIV, including laboratory and primary isolates.

In fact, given the geographic diversity of distribution of different strains of HIV, it makes sense to utilize many strains of HIV with this methodology. The combined use of different strains of inactivated particles of HIV is what will confer to this potential vaccine preparation its polyvalent characteristics. Thus, in describing the method to generate the vaccine particles and its testing for safety and efficacy, the

inventor sought to establish the general principles of the methodology for its subsequent application. It should be understood that the inactivator of the HIV reverse transcriptase to be used in the initial study can be compared to other inactivators in parallel studies and thus allow for the selection of the most effective one.

It of importance to note that the methodology of the present invention is applicable to any retrovirus which may be associated with any animal or human disease as a method for development of an effective preventive vaccine. Thus, the present invention has a broader applicability than the exemplified HIV vaccine.

4.1 HUMAN IMMUNODEFICIENCY VIRUS

The genetic diversity of HIV is due to the extremely high replication rate in infected individuals, the high rate of mutation caused by the error-prone reverse transcriptase, the substantial viral load, and selection within infected individuals (Doolittle, 1989; Ho *et al.*, 1995; Piatek *et al.*, 1993). Diversity is so great that the presence of closely related but not identical strains of HIV, known as quasispecies, commonly appear in a single, infected individual. The quasispecies may diverge increasingly over time and changes tend to be within the *env* gene, particularly the V3 region (Hwang *et al.*, 1992). Although changes also may occur in the *gag*, *pol*, and accessory genes, these differences tend to be less substantial.

When significant changes accumulate and are seen in a large group of individuals, the strain is commonly considered a new family or new clade of HIV. Phylogenetic studies of HIV have shown that there are two major families of HIV, HIV-1 and HIV-2. Within the HIV-1 family there are two major antigenic groups, known as Group M (major) and Group O (outlier). Each of these two groups has in turn different subtypes or clades which, when analyzed, lead to the conclusion that both probably originated from two primordial viral ancestors. The group M is responsible for most of the HIV infections throughout the world and the group O is rarely found and confined to Cameroon, Gabon and France. There are at least nine subtypes or clades in the group M and of these, the subtype B is prevalent in the Western Hemisphere, while the subtypes A, C and D are in Africa. In Asia, the most

frequently found subtypes are E, C and B, with the subtype E having a high prevalence in Southeast Asia. In India the prevalent subtype is C. A phylogenetic tree based on the sequence data from the *env* gene C2V2 region of selected isolates of the different subtypes is shown in FIG. 1. The geographic distribution of the different clades is shown in Table 1 (Hardy, 1996).

TABLE 1

Worldwide Geographic Distribution of HIV-1 Subtypes and HIV-2

	HIV-1 Subtypes										HIV-2
	Group M								I	O	
	A	B	C	D	E	F	G	H			
Africa	+	+	+	+	+	+	+	+		+	+
Middle East									+		
Europe	+	+	+	+		+	+	+		+	+
Asia		+	+		+						
India	+	+	+								+
Australia		+									
North America		+									+
South America		+	+		+						

A vaccine comprising one clade may provide for the protection of infection by one or more other clades. A very important concept when confronting what appears to be the very difficult challenge of antigenic variation is the understanding of the concept of critical antigenic consistency. By critical antigenic consistency it is meant that there is a critical number of epitopes which are found consistently in HIV. Although it is recognized that there are significant antigenic changes in the configuration of the envelope proteins, generally, the internal proteins have less sequence variation. It has been recently demonstrated that epitopes, of critical immunologic importance, are exposed or created as HIV begins to fuse with cell membranes. The fusion process results in a conformational change of envelope glycoproteins leading to the exposure of previously occult epitopes or the de novo formation of epitopes. The recent use of these fusion exposed epitopes has led to the

preparation of antibodies which are capable of inhibiting the infectivity of multiple primary HIV isolates, including multiple genetic subtypes (Montefiori and Moore, 1999; LaCasse *et al.*, 1999). The broad immunological protection elicited by the fusion exposed epitopes may explain the observation that people infected with HIV-1
5 virtually never have more than one subtype of virus.

These significant recent results indicate that once the immune system is exposed to HIV without integration of HIV in the genetic machinery of the host, the immune response will be effective and of a broad base. The non-infectious HIV particles of the part invention mimic the antigenic structure and composition of
10 natural infectious HIV particles. Thus, these non-infectious particles will penetrate susceptible cells, including cells of the immune system responsible for the generation of the immune response, in the identical fashion as infectious particles, that is by receptor/co-receptor binding and fusion. The receptor-mediated entry of the vaccine into cells will result in exposure of the superior immunogenic epitopes and thereby
15 facilitate the creation of a broad immunogenic response.

In addition to the recently described fusion exposed epitopes, the consistent regions of the *env*, *gag*, and *pol* together can lead to a critical mass of antigens responsible for the production of an effective immunological response to HIV and, which in fact, are present in nearly all types and subtypes of HIV. Thus, although it
20 will be wise to use different wild types to create non-infectious particles and create a polyvalent vaccine, it is also possible that exposure of the immune system to a single type of inactivated HIV particle will be enough to generate a broad immune response.

The antigenic configuration of HIV is of the utmost importance since it is known that conformational epitopes can be located in variable regions of the HIV
25 particle and can not be predicted from the analysis of the linear sequences of these regions. Therefore, it is of great importance that, in eliciting an effective protective immune response against HIV, the immune system is presented correct antigenic conformations.

Substantial evidence indicates that dendritic cells ("DC") present in epithelial
30 tissues (*e.g.*, Langerhans cells) are the initial cells infected with HIV after mucosal exposure to the virus (Cameron *et al.*, 1996; Knight, 1996). The bone marrow-

derived DC are a class of antigen-presenting cells ("APC") that survey epithelial tissues for antigens and are efficient stimulators of both B and T lymphocytes. Unlike B cells, T cells cannot directly recognize antigens and require that antigens be processed and presented by APCs (Banchereau and Steinman, 1998). Intracellular processing of antigens to peptide fragments results in binding to MHC class I molecules and a CD8+ cytotoxic T cell response. In contrast, antigens that enter DC by the endocytic pathway generally bind to MHC class II molecules the elicitation of a CD4+ helper T cell response (Banchereau and Steinman, 1998).

Inactivated HIV viral particles will be processed and presented by DC as long as the inactivated HIV particles are preserved in its antigenic composition and can access the cytoplasm of the dendritic cells. Both of these conditions are met by the present invention. That is, the inactivated particles have a preserved envelope structure and thus will access the cytoplasm of the dendritic cell by a process of micropinocytosis or mannose-receptor mediated uptake. DC that have been exposed to the inactivated HIV particles will migrate to the lymph nodes where they will interact with T-cells presenting MHC-antigens complexes to both memory and naive T-cells (see Banchereau and Steinman, 1998; Bender *et al.*, 1995). This process will lead to the development of an effective anti-HIV MHC-I restricted CD8+ T-cell response. Cytotoxic CD8+ T cells are recognized as having an important role in controlling HIV invention (Musey *et al.*, 1997; Oldstone, 1997).

Dendritic cells also have CD4/HIV co-receptors and thus can be infected by HIV. This infectious process is independent of the capture and processing of HIV for antigenic presentation and initiation of the MHC class I restricted immunological response (Blauvelt *et al.*, 1997). But since the inactivated particles are non-infections, the process of penetration through a receptor mechanism will allow the production of a MHC-II restricted response. Thus DC cells will activate and expand CD4+ T helper cells, which in turn will induce B cell growth and antibody production. This MHC class II response will thereby complement the MHC class I restricted immune response by establishing an effective cytotoxic and humoral response as well as an effective immunological memory.

The inventor contemplates that the present invention may be comprised of inactivated viruses from one or more clades of HIV. In preferred embodiments, the vaccine may be comprised of inactivated viruses of the clade or clades which with the individual is most likely to come in contact. The data of Table 1 may be used as a guide to determine which clades are prevalent in different geographical areas.

Because the present invention may be produced cheaply and rapidly, an individual may be vaccinated with inactivated virus or even inactivated HIV infected cells from the individual most likely to pass or have passed the virus to the individual. For example, an HIV-negative person may be vaccinated with inactivated HIV or inactivated HIV-infected cells from an HIV-positive individual with which the HIV-negative individual plans to or has already come in sexual contact. An example of such a HIV-negative individual could be someone married to a hemophiliac that is HIV-positive. Additionally, these "personal" vaccines may have the benefit of also having cellular (nonviral) surface proteins from the individual passing the virus. The immune response to cellular surface proteins incorporated into the virus particles, which include MHC antigens, have been shown to confer protection from future challenges from viruses grown in the same cell line (Stott *et al.*, 1991).

4.2 PHOTOINACTIVATION OF REVERSE TRANSCRIPTASE

A number of non-nucleoside inhibitors of HIV reverse transcriptase have been described and include nevirapine and its analogs, the pyridobenzo- and dipyridodiazepinones, the pyridones, the quinoxalines, and the carboxanilides. Specific compounds include 9-AN, UC781™, UC38, UC84, UC10, UC82, UC040, HBY 097, calanolide A, U-88204E, and many others (Barnard *et al.*, 1997; Esnouf *et al.*, 1997; Buckheit *et al.*, 1997; Kleim *et al.*, 1997; Currens *et al.*, 1996; Althaus *et al.*, 1993). These compounds may be converted to azido photoaffinity labels and utilized for the inactivation of HIV particles using methods described herein. The inventor contemplates that essentially any compound that binds and inhibits HIV RT, is able to penetrate the viral particle and associate with RT, and does not cause significant alterations in the conformation of the virus particle may be used to produce an RT-inactivated virus for the purpose of eliciting a protective immune response in

an individual. Furthermore, the inventor contemplates that the exposure of the photaffinity label-treated particles to light radiation to irreversibly inactivate the RT may comprise of light of a variety of wavelengths. Although UV light, particularly that emitted by a GE 275 W sun lamp, is preferred, any exposure to light that causes the reaction of the azido compound with RT is contemplated to be of utility in the production of the compositions of the present invention.

4.3 VACCINE PREPARATION

The inactivation of the virus by photoinactivation of RT provides noninfectious, immunogenic particles that are essentially identical in conformation and composition as infectious particles. Therefore, the inventor contemplates that particles inactivated in this method are ideal for use as a potential vaccine against HIV diseases including AIDS and AIDS-related conditions. Thus the present invention provides an immunogenic composition that may be used as a vaccine against HIV infection and its consequences, including AIDS and AIDS-related conditions. The immunogenic compositions elicit an immune response which produces cellular and humoral immune responses that are antiviral. If a vaccinated person is challenged by HIV, T cells of the cellular response will eliminate infected cells and antibodies of the humoral response will inactivate the virus by binding to its surface.

Vaccines may be injectable liquid solutions or emulsions. The RT-inactivated HIV particles may be mixed with pharmaceutically-acceptable excipients which are compatible with the inactivated virus particles. By compatible it is meant that the pharmaceutically-acceptable excipients will not alter the conformational characteristics of the viral particle. Excipients may include water, saline, dextrose, glycerol, ethanol, or combinations thereof. The vaccine may further contain auxiliary substances, such as wetting or emulsifying agents, buffering agents, or adjuvants to enhance the effectiveness of the vaccines. Adjuvants may be mineral salts (e.g., $\text{AlK}(\text{SO}_4)_2$, $\text{AlNa}(\text{SO}_4)_2$, $\text{AlNH}_4(\text{SO}_4)$, silica, alum, $\text{Al}(\text{OH})_3$, $\text{Ca}_3(\text{PO}_4)_2$, kaolin, or carbon), polynucleotides (e.g., poly IC or poly AU acids), and certain natural substances (e.g., wax D from *Mycobacterium tuberculosis*, substances found in *Corynebacterium parvum*, *Bordetella pertussis*, or members of the genus *Brucella*) (PCT Application

No. 91/09603). Aluminum hydroxide or phosphate (alum) are commonly used at 0.05 to 0.1 percent solution in phosphate buffered saline. Other adjuvant compounds include QS21 or incomplete Freund's adjuvant.

5 Vaccines may be administered parenterally, by injection subcutaneously or intramuscularly, or the vaccines may be formulated and delivered to evoke an immune response at the mucosal surfaces. The immunogenic composition may be administered to a mucosal surface by the nasal, oral, vaginal, or anal routes. The inventor contemplates that the administration of the immunogenic compound to a mucosal surface that is most likely to be challenged by HIV, such as the anal, vaginal, 10 or oral mucosa, is preferred. For vaginal or anal delivery, suppositories may be used. Suppositories may comprise binders and carriers such as polyalkylene glycols or triglycerides. Oral formulations may be in the form of pills, capsules, suspensions, tablets, or powders and include pharmaceutical grades of saccharine, cellulose or magnesium carbonate. These compositions may contain 10% to 95% of the RT-inactivated viral particles. 15

Preferably the vaccines are administered in a manner and amount as to be therapeutically effective. That is to say that the vaccine should be administered in such a way as to elicit an immune response to the RT-inactivated viral particles. Suitable doses required to be administered are readily discernible by those of skill in 20 the art. Suitable methodologies for the initial administration and booster doses, if necessary, maybe variable also. The dosage of the vaccine may depend on the route of administration and may vary according to the size of the host. One of skill in the art may obtain details regarding the practice and use of the present invention in the American Foundation for AIDS Research's HIV Experimental Vaccine Directory, Vol 25 1, No. 2, June 1998, which is hereby incorporated by reference in its entirety.

Although the immunogenic compositions of the present invention may be administered to individuals that are not infected with HIV, HIV-negative, they also may be administered to individuals who are infected with the virus in an effort to alter the immune response to the virus. The alteration may be a stimulation of anti-HIV 30 CD4⁺ or CD8⁺ T cells, an increase in antibody production, or in respect to the type of response to the virus (*i.e.*, T_H1 vs. T_H2). Nonetheless, this alteration if effective will

decrease the mortality and morbidity associated with the HIV infection. In other words, the immunogenic compound may decrease the severity of the disease and increase the life of the patient.

5 4.4 PHARMACEUTICAL COMPOSITIONS

Where clinical application of a vaccine according to the present invention is contemplated, it will be necessary to prepare the complex as a pharmaceutical composition appropriate for the intended application. Generally this will entail preparing a pharmaceutical composition that is essentially free of pyrogens, as well as
10 any other impurities that could be harmful to humans or animals. One also will generally desire to employ appropriate salts and buffers to render the complex stable and allow for complex uptake by target cells.

Aqueous compositions of the present invention comprise an effective amount of the inactivated virus, dissolved or dispersed in a pharmaceutically acceptable
15 carrier or aqueous medium. Such compositions also are referred to as inocula. The phrases "pharmaceutically or pharmacologically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media,
20 coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the
25 compositions.

Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions also can be prepared in glycerol, liquid
30 polyethylene glycols, mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The inactivated viruses and inactivated virus-producing cells of the present invention may include classic pharmaceutical preparations. Administration of pharmaceutical compositions according to the present invention will be via any common route so long as the target tissue is available via that route. This includes
5 oral, nasal, buccal, rectal, vaginal or topical. Alternatively, administration will be by orthotopic, intradermal, intraocular, subcutaneous, intramuscular, intraperitoneal or intravenous injection. Such compositions would normally be administered as pharmaceutically acceptable compositions that include physiologically acceptable carriers, buffers or other excipients.

10 The pharmaceutical compositions of the present invention are advantageously administered in the form of injectable compositions either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. These preparations also may be emulsified. A typical composition for such purpose comprises a pharmaceutically acceptable carrier. For
15 instance, the composition may contain 10 mg, 25 mg, 50 mg or up to about 100 mg of human serum albumin per milliliter of phosphate buffered saline. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters
20 such as ethyloleate. Aqueous carriers include water, alcoholic/aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer's dextrose, *etc.* Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial agents, anti-oxidants, chelating agents and inert gases. The pH and exact concentration of the various components of the pharmaceutical composition are
25 adjusted according to well known parameters.

The compositions of the present invention may comprise a supplement of one or more compounds capable of preventing the replication of HIV, including the compound utilized to inactivate the virus. These compounds may include, but are not limited to, nucleoside analog inhibitors of HIV RT (*e.g.*, AZT), non-nucleoside
30 inhibitors of HIV-RT (*e.g.*, UC781™), or HIV protease inhibitors.

4.5 SAFETY OF THE VACCINE

The safety of the vaccine particles may be demonstrated by their inability to produce infection in susceptible cells regardless of the amount of particles used as inoculum. Controlled studies may be conducted exposing susceptible cells to increased concentrations of these particles. Particles which have their RT inactivated will fail to infect susceptible cells, while the control studies will maintain the capacity to produce infection in the susceptible cells. The same methodology that was used to generate the viral particles may be used to test the inactivation of the virus particles of the present invention. For monitoring infectivity in both the non-infectious particles and the controls, the inventor contemplates the monitoring of production of RT and p24 antigen in the culture supernatants. In a preferred embodiment, supernatants are tested for the presence of virus particles by the sensitive method of heminested polymerase chain reaction (HNPCR) amplification of the 5' LTR sequences (LTR-HNPCR). This test will confirm the absence of infectivity of the vaccine particles since there is an excellent correlation between a negative infectivity test and a negative LTR-HNPCR (Yang *et al.*, 1998).

The safety of the particles can also be evaluated *in vivo* by inoculation of the animal models discussed *infra* in section 4.6. The lack of infectivity of the inactivated particles can be determined by repeated high dose inoculation of animals such as PBL-SCID mice, SCID-hu mice, or non-human primates.

As a way of creating an additional safety mechanism for this vaccine, HIV integrase, an enzyme required for viral integration, can be inactivated. It is important to clarify that since the reverse transcriptase of the viral particle is inactivated there will be no replication of the virus. The inactivation of HIV integrase would be an added safety feature. Without a functional integrase there is no possibility for the integration of HIV into the genetic material of the cell further ensuring the safety of the vaccine. The mechanism for integrase inactivation will be one of selective photolabeling using a (as azido group) bound to any of several compounds that are known to bind to HIV-integrase. Among these compounds are: anti-integrase oligonucleotides, L-chicoric acid, as well as a large number hydrazine derivative inhibitors.

4.6 ADMINISTRATION

Although it is important to consider different routes of administration, the intramuscular route will be the route of choice. Other routes include: 1) intranasal; 2) intrarectal; 3) intravaginal; 4) oral and 4) subcutaneous. The dose to be used will be measured in viral particles and it will have a range from the administration of 1 particle to 10^{20} particles. It is anticipated that the optimal range of dosing will be between 10^4 particles and 10^8 particles. Thus lower dose ranges may include doses of about 10, 10^2 , or 10^3 particles. Optimal dose ranges may include doses of about 10^4 , 10^5 , 10^6 , 10^7 , or 10^8 particles. Higher dose ranges may include doses of about 10^{10} , 10^{12} , 10^{14} , 10^{16} , 10^{18} , or 10^{20} particles. The effective dosage may vary depending on the method of administration.

For each dose to be tested, the schedule may consist of administration of a dose on days 0, 30, 60, and a booster dose at 180 days. Alternatively doses may be given weekly, every two weeks, or monthly for periods of one, two, three, four, five or six months. Doses may also be given every two months for a similar time. Periodic booster shots at intervals of 1-5 years may be desirable to maintain protective levels of immunity. Other administration schedules may be used and the invention contemplates any administration schedule that results in an effective vaccination.

In addition to monitoring for clinical safety, efficacy will be assessed by measuring the cellular and humoral immune response to HIV. Subjects will be followed for a period of two or more years from day 0 (date of first inoculation).

4.7 ANIMAL MODELS

A number of different animal model systems for HIV infection have been employed (Kindt *et al.*, 1992). Non-human primates such as chimpanzees and pig-tailed macaques can be infected by HIV-1. Although CD4+ cells are not depleted in these systems, the animals are detectably infected by the virus and are useful in determining the efficacy of HIV vaccines. Small animal models include chimeric models that involve the transplantation of human tissue into immunodeficient mice. One such system is the hu-PBL-SCID mouse developed by Mosier *et al.* (1988).

Another is the SCID-hu mouse developed by McCune *et al.* (1988). Of the two mouse models, the SCID-hu mouse is typically preferred because HIV infection in these animals is more similar to that in humans. SCID-hu mice implanted with human intestine have been shown to be an *in vivo* model of mucosal transmission of HIV (Gibbons *et al.*, 1997). Methods of constructing mammals with human immune systems are described in U.S. Patents 5,652,373, 5,698,767, and 5,709,843.

The animals will be inoculated with the vaccine of the present invention and later challenged with a dose of infectious virus. Efficacy of the vaccine will be determined by methods known by those of skill in the art. Generally, a variety of parameters associated with HIV infection may be tested and a comparison may be made between vaccinated and non-vaccinated animals. Such parameters include viremia, detection of integrated HIV in blood cells, loss of CD4+ cells, production of HIV particles by PBMC, *etc.* The vaccine will be considered effective if there is a significant reduction of signs of HIV infection in the vaccinated versus the non-vaccinated groups.

The ability of the inactivated HIV particles to elicit neutralizing antibodies can be measured in mice as previously described (LaCasse *et al.*, 1999). The ability of sera to neutralize a range of HIV isolates can be tested using U87-CD4 cells expressing either CCR5 or CXCR4 coreceptors or by using an peripheral blood lymphocyte culture assay (LaCasse *et al.*, 1999, LaCasse *et al.*, 1998; Follis *et al.*, 1998).

4.8 APPLICATION IN HUMANS

Of course, the inventor contemplates the application of the present invention as a vaccine to HIV in humans. The inventor contemplates that testing of the present invention as a vaccine in humans will follow standard techniques and guidelines known by those of skill in the art. One important aspect of human application is the production of an effective immune response to the vaccine. Although various *ex vivo* tests may be performed, such as measuring anti-HIV antibody production and anti-HIV cellular responses, the ultimate test is the ability of the vaccine to prevent infection by HIV or to significantly prolong the onset of AIDS in individuals.

receiving the vaccine. The monitoring of the efficacy of HIV vaccines in humans is well known to those of skill in the art and the inventor does not contemplate that the present invention would require the development of new methods of testing the efficacy of an HIV vaccine.

5

5.0 EXAMPLES

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

15


5.1 PHOTOAFFINITY LABELS

One compound that may be used to photoinactivate the reverse transcriptase of HIV-1, is an azido dipyridodiazepinone, 9-Azido-5,6-dihydro-11-ethyl-6-methyl-11H-pyrido[2,3-b][1,5]benzodiazepin-5-one (9-AN). Production of 9-AN is described in Hargrave *et al.* (1991). It may be prepared by mixing an equimolar mixture of 2-chloronicotinic acid and 4-nitrophenylendiamine heated in sulfolane at 170 °C for 5 hours. After cooling, the precipitate is collected and washed with hot ethanol. The obtained mixture of 8- and 9- nitro-5,6-dihydro-11 H -pyrido[2,3-b]benzodiazepin-5-ones, are then methylated with methyl iodide and dimethylsodium in DMSO, and the 5,6-dihydro-6-methyl-9nitro isomer is purified by fractional crystallization. The 8-amino compound is obtained by ethylation with ethyl iodide and dimethylsodium in DMSO followed by stannous chloride reduction of the nitro group. The 8-amino compound is then converted to the azide by diazotization with sodium nitrate followed by reaction with sodium azide. The 9-azido derivative is then crystallized from diethyl ether to give analytically pure material: mp 115-118°C; CIMS molecular ion H⁺ 295; C, H, and N analysis and spectroscopic characterization were consistent

25
30

with the structure. A methanolic solution of the azido photolabel has a lambda max of 248 nm ($\epsilon=30\ 000$).

Another molecule that can be prepared as a photolabel by diazotization is a thiocarboxanilide, known by the trademark name of UC781TM. UC781TM was developed by Uniroyal Chemical Ltd. Research laboratories. It is known that UC781TM is a molecule with high affinity for HIV-1 reverse transcriptase and with the characteristics of tight binding. In fact, it is reasonable to assume that UC781TM alone inactivates the HIV-1 reverse transcriptase (Barnard *et al.*, 1997; Borkow *et al.*, 1997). The diazotization of this molecule and its subsequent activation with ultraviolet light further insures the inactivation of the HIV-1 reverse transcriptase. The azido photoaffinity labels, upon exposure to ultraviolet light, transform into highly reactive nitrenes capable of inserting into proximal covalent bonds of the HIV-1 reverse transcriptase enzyme structure.



Structure of UC781TM

5.2 EXAMPLE 2 — INACTIVATION OF HIV PARTICLES AND HIV-INFECTED CELLS

The inactivation of HIV can be accomplished by taking advantage of compounds that bind the HIV reverse transcriptase with a high degree of specificity. Using the technique of photolabeling, a compound with high specific affinity for the HIV-1 reverse transcriptase can then be turned into an "active" moiety which will produce an irreversible inactivation of the reverse transcriptase upon exposure to ultraviolet light irradiation. This inactivation, in the case of the compounds already

described and known to have this effect, meets the requirement of being specific for the reverse transcriptase of HIV-1. That is, their labeling and photoactivation is not accompanied by the alteration of any other component of the viral particle than the reverse transcriptase of HIV-1. That is an important element of this invention since the irreversible inactivation of HIV-1 reverse transcriptase will lead to non-infectious particles of HIV-1 with a natural antigenic structure which should behave as the infectious particles of HIV-1 insofar as their capacity for stimulation of an effective immune response. There are many compounds that can be used for the purpose of photolabeling inactivation of the HIV-1 reverse transcriptase and include UC781TM thiocarboxanilide, UC781TM azidothiocarboxanilide, and azido dipyridodiazepinona.

5.2.1 INFECTION OF VIRUS PRODUCING CELLS

Laboratory-adapted and primary wild type HIV isolates will be cultured using established standard techniques. The cells to be used for culture will be phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMC's), since they are more readily infected by both primary isolates and laboratory-adapted isolates than cloned T-cell lines (MT-2 or H9). Briefly, PBMC from normal blood donors are isolated by Ficoll-Hystopaque gradient centrifugation and stimulated with 5 µg/ml of PHA for three to four days. The PHA-stimulated PBMC are then cultured in RPMI-1640 medium containing 10% heat-inactivated FBS, 100 U penicillin/ml, 100 µg of streptomycin/ml 2 mM L-glutamine, and 5% purified human interleukin-2.

Aliquots of 10^7 uninfected PBMC's in 10 ml of medium are pretreated with 2 µg/ml of polybrene for 1 h at 37°C. The cells are then infected with a 1.0 ml inoculum of cell-free supernatant of the primary isolate or the laboratory-adapted isolate. The infected PBMC's are then resuspended in the culture media and monitored for supernatant p24 antigen concentration, which generally peaks at day 14 postinoculation. The culture supernatants are harvested, pooled, and clarified through a 0.45 µm filter, and aliquoted. The 50% tissue culture infectious dose is determined according to the protocol described by Johnson *et al.*, (1990) using the HIV p24 antigen detection technique.

Of course, the inventor contemplates that the use of PBMCs may not be feasible when large volumes of virus are needed. In this instance, the cell line utilized is MT-2 grown in RPMI 1640 medium with 10% heat-inactivated fetal calf serum (FBS), glutamine and antibiotics. Cells are propagated at 37°C in an atmosphere of 5% CO₂ in air. The virus employed for this work is HIV-1 isolates IIIB and/or RF, which are prepared by an acute infection process. Virus infection of the MT-2 cells is carried out in a bulk infection process. The appropriate number of cells is mixed with infectious virus in a conical centrifuge tube in a small total volume of 1-2 milliliters. Following a 4-hour incubation, the infected cells are brought to the appropriate final concentration of 5×10^4 cells per milliliter with fresh tissue culture medium. Uninfected cells at the same concentration are plated for the toxicity controls and for the cell controls. The MOI is adjusted to give complete cell killing in the virus control wells by Day 6. Virus particles are concentrated using standard techniques and quantified using RT assays (Fletcher *et al.*, 1995a, 1995b) and p24 antigen assays.

5.2.2 HIV PARTICLE INACTIVATION

Once the HIV particles are purified and quantified, the 50% tissue culture infective dose ([TCID₅₀] = 5×10^4) is incubated in the presence of four to eight times the 50% inhibitory concentration (IC₅₀) of the photoaffinity labeling molecule. In the case of the azido dipyridodiazepinona, the IC₅₀ is 160 nM. For the thiocarboxanilide and the azido thiocarboxanilide, the IC₅₀ is 0.2 nM. Incubations were in RPMI 1640 without FBS for 2 h at 37°C with gentle agitation every 15 min. The mixtures of viral particles and photoaffinity labels are exposed to ultraviolet light using a GE 275-W sun lamp that provides a UV-irradiation intensity of about $15 \mu\text{W}/\text{cm}^2$ for a period of at least 50 minutes. After this process, the solution contains particles of HIV-1 with a completely inactivated reverse transcriptase and thus unable to infect susceptible cells.

The infectivity of the inactivated virus particles will be determined by controlled experiments where exposure of susceptible cells to increased concentrations of these particles will fail to produce infection of the cells as evidenced by the sensitive heminested PCR technique described in Yang *et al.* (1998) and the lack of production of viral particles, reverse transcriptase, and p24. Such a process to

assay the production of virus particles is outlined by Borkow *et al.* (1997). Briefly, 0.5 ml of concentrated inactivated virus is added to 0.5 ml of phytohemagglutinin-activated cord-blood mononuclear cells (CBMC)(4×10^6 cells) in RPMI 1640-10% FBS and incubated for 2 h at 37°C with occasional gentle mixing. The HIV-CBMC incubation mix is diluted with the addition of 10 ml of RPMI 1640, and residual HIV is removed by pelleting the cells at $300 \times g$ for 10 min, followed by removal of the supernatant and resuspension of the cells in 2 ml of RPMI 1640-10% FBS containing interleukin-2 (10 U/ml). The entire sample is plated into a single well of a 24-well dish. After 4 days of culture, 1 ml of medium is removed and replaced with 1 ml of fresh medium. On day 7, culture supernatants are isolated and HIV production is assessed by the measurement of RT activity and p24 antigen levels in these cell-free supernatants and cells are monitored for integration by the heminested PCR technique of Yang *et al.* (1998).

5.3 EXAMPLE 3 -- PRODUCTION OF NONINFECTIOUS NASCENT VIRUS FROM UC781TM-TREATED HIV INFECTED CELLS

In addition to the inactivation of purified virus, UC781TM has been shown to inactivate nascent virus from HIV-infected cells grown in the presence of the compound (Borkow *et al.*, 1997, incorporated wherein by reference). The methods described by Borkow *et al.* may be used to produce inactivated virus for use in the present invention. Furthermore, the methods may be used to create a whole-cell vaccine in which the cells are HIV infected but rendered noninfectious by UC781TM. A whole cell vaccine comprises the injection of HIV-infected cells. The injection of whole cells may provide a more vigorous immune response to the virus. The methods of Borkow *et al.* (1997) are described below.

5.3.1 INCUBATION OF CHRONICALLY HIV-1 INFECTED H9 CELLS WITH UC781TM

Chronically infected H9 cells (5×10^5 cells) are incubated with 10 μ M of UC781TM in a total volume of 1 ml of RPMI 1640-10% FBS for 18 h at 37°C. The cells are then separated from the culture supernatants by centrifugation at $300 \times g$ for 10 min. The pelleted H9 cells are washed by suspension in 10 ml of RPMI 1640

followed by centrifugation at $300 \times g$ for 10 min. The cell pellet is resuspended in 4 ml of RPMI 1640-10% FBS and used in coculture experiments to determine infectivity (Borkow *et al.*, 1997).

5 5.3.2 INCUBATION OF PERIPHERAL BLOOD LYMPHOCYTES WITH UC781™

Peripheral blood lymphocyte (PBL) cells (2×10^6 cells) isolated from blood of HIV-1-infected patients are incubated with medium and 10 μ M UC781™ in a total volume of 1 ml for 2 h at 37°C. Excess drug may be removed by pelleting the cells by centrifugation at $300 \times g$ for 10 min and removal of the medium. The cell pellet is washed by suspension in 10 ml of medium followed by centrifugation. This washing step is repeated twice. The final cell pellet is resuspended in 1 ml of medium or another isotonic solution. To insure that the cells are noninfectious, they are cocultured with 1 ml of activated CBMC (2×10^6 cells). The culture medium is changed every 2 days, and fresh activated CBMC (2×10^6 cells) are added once per week. HIV-1 production is monitored by measurement of p24 antigen levels in cell-free culture supernatants. Integration of the virus is tested by the heminested PCR technique of Yang *et al.* (1998).

5.3 EXAMPLE 3 — CLINICAL TRIAL FOR HIV VACCINE

This example describes a protocol to facilitate an HIV vaccine clinical trial. The various elements of conducting a clinical trial, including patient treatment and monitoring, will be known to those of skill in the art in light of the present disclosure. Generally, the clinical study of the vaccine composed of inactivated viral particles should consist of the administration of such viral particles produced by the photolabeling of reverse transcriptase, as described in the present invention, to human subjects to evaluate safety and cellular, antibody, humoral and other clinical responses. The following information is being presented as a general guideline for use in HIV vaccine clinical trials. Information regarding design of clinical trials can also be obtained in the American Foundation for AIDS Research's HIV Experimental Vaccine Directory, Vol 1, No. 2, June 1998.

5.3.1 Eligible Subjects

Adult males and females HIV seronegatives.

5.3.2 Subjects Inclusion Criteria

5 Patient Age: 18 years - 60 years.

5.3.4 Reproductive Criteria

Negative pregnancy test. Abstinence or effective method of birth control /contraception during the study.

10

5.3.5 Inclusion Criteria

The subject must be healthy as defined by a normal physical exam and normal laboratory parameters as defined by the WHO for participants in clinical studies. Subjects must be able to understand and sign an informed consent. Subjects must also
15 have a normal total white blood cell count, lymphocyte, granulocyte and platelet count as well hemoglobin and hematocrit. Subjects must has normal values of the following parameters: urinalysis; BUN; creatinine; bilirubin; SGOT; SGPT; alkaline phosphatase; calcium; glucose; CPK; CD4+ cell count; and normal serum immunoglobulin profile.

20

5.3.6 Exclusion

The following are exclusion criteria: HIV-seropositive status; Active drug or alcohol abuse; inability to give an informed consent; medication which may affect immune function with the exception of low dose of nonprescription-strength
25 NSAIDS, aspirin, or acetaminophen for acute conditions such as headache or trauma; any condition which in the opinion of the principal investigator, might interfere with completion of the study or evaluation of the results.

5.3.7 Randomization

The study will be double blind randomized. The placebo will be the vaccine solution without the inactivated viral particles. Subjects will be assigned randomly to one of the vaccine routes described above.

5

5.3.8 Dose range

Doses of 10^4 , 10^6 and 10^8 particles will be studied for clinical safety and immunogenicity. Other doses in the range of 10 to 10^{20} particles may also be studied.

10

5.3.10 Administration

For each dose to be tested, the schedule may consist of administration of a dose on days 0, 30, 60, and a booster dose at 180 days. Route of administration will be intramuscular. Additional routes of administration may include: subcutaneous; oral; intrarectal; intravaginal; intranasal/intramuscular; intrarectal/intramuscular; intranasal/subcutaneous; intrarectal/subcutaneous

15

5.3.11 Number of subjects per route of administration

There will be 12 subjects per route of administration per dose level. Of the 12 subjects 8 will receive the vaccine and 4 will receive a solution without inactivated viral particles.

20

5.3.12 Duration of the study

24 months.

25

5.3.13 Endpoints

The endpoint for clinical safety is no evidence of alteration of the clinical, immunological or laboratory parameters. The endpoint for immunological efficacy is seroconversion with production of an effective cellular, humoral and antibody response against HIV. The effective immunological cellular response can be studied by using cytotoxic T lymphocytes responses against different strains of HIV. The

30

humoral response can be evaluated by measuring the production of IFN-gamma release using a modified Elispot assay. The antibody production can be assessed by performing neutralization studies against different clades of HIV.

- 5 All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of
- 10 steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to
- 15 be within the spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

U.S. Patent 5,041,078.

U.S. Patent 5,516,629.

U.S. Patent 5,593,823.

U.S. Patent 5,652,373.

U.S. Patent 5,698,767.

U.S. Patent 5,709,843.

PCT Application No. 91/09603.

Abbas, *Cell*, 84:655, 1996.

Althaus *et al.*, *Biochemistry*, 32(26):6548-6554, 1993.

American Foundation for AIDS Research's HIV Experimental Vaccine Directory, Vol 1, No. 2, June 1998.

Bader, McMahon, Schulz, Narayanan, Pierce, Weislow, Midelfort, Stinson, Boyd, *Proc. Natl. Acad. Sci. U.S.A.*, 88:6740-6744, 1991.

Balzarini, Brouwer, Dao, Osika, De Clercq, *Antimicrob. Agents Chemother.*, 40:1454-1466, 1996.

Balzarini, Perez-Perez, Velazquez, San-Felix, Camarasa, De Clercq, Karlsson, *Proc. Natl. Acad. Sci. U.S.A.*, 92:5470-5474, 1995.

Banchereau and Steinman, "Dendritic cells and the control of immunity," *Nature*, 392:245-252, 1998.

Barnard, Borkow, Parniak, "The Thiocarboxanilide Nonnucleoside UC781 is a Tight-Binding Inhibitor of HIV-1 Reverse Transcriptase," *Biochem.*, 36:7786-7792, 1997.

Bender, Bui, Feldman, Larsson, Bhardwaj, "Inactivated influenza virus, when presented on dendritic cells, elicits human CD8⁺ cytolytic T cell responses," *J. Exp. Med.*, 1663-1671, 1995.

- Blauvelt, Asada, Saville, Klaus-Kovtun, Altman, Yarchoan, Katz, "Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways," *J. Clin. Invest.*, 100(8):2043-2053, 1997.
- 5 Borkow, Barnard, Nguyen, Belmonte, Wainberg, Parniak, "Chemical Barriers to Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Retrovirucidal Activity of UC781, a Thiocarboxanilide Nonnucleoside Inhibitor of HIV-1 Reverse Transcriptase," *J. of Virol.*, 71(4):3023-3030, 1997.
- Buckheit *et al.*, *AIDS Res Hum Retroviruses*, 13(9):789-796, 1997.
- 10 Cameron, Pope, Granelli-Piperno, Steinman, "Dendritic cells and the replication of HIV-1," *J. Leukocyte Biol.*, 59:158-171, 1996.
- Carlson, McGraw, Keddie, Yee, Rosenthal, Langlois, *et al.*, "Vaccine protection of rhesus macaques against simian immunodeficiency virus infection," *AIDS Res. Hum. Retrovir.*, 6:1239-46, 1990.
- 15 Carroll, Olsen, Bennett, Gotlib, Graham, Condra, Stern, Shafer, Kuo, *J. Biol. Chem.*, 268:276-281, 1993.
- Cohen, *Science*, 278:25-25, 1997.
- Currens *et al.*, *J Pharmacol Exp Ther*, 279(2):652-661, 1996.
- Desrosiers, Wyand, Kodama, Ringler, Sehgal, *et al.*, "Vaccine protection against
20 simian immunodeficiency virus infection," *Proc. Natl Acad. Sci. USA*, 86:6353-7, 1989.
- Doolittle, "The simian-human connection," *Nature*, 339:338, 1989
- Esnouf *et al.*, *Biochem Biophys Res Commun*, 234(2):458-464, 1997.
- Fletcher, Arion, Borkow, Wainberg, Dmitrienko, Parniak, "Synergistic inhibition of
25 HIV-1 reverse transcriptase DNA polymerase activity and virus replication *in vitro* by combinations of carboxanilide nonnucleoside compounds," *Biochem.*, 34:10106-10112, 1995a.
- Fletcher, Syed, Methani, Dmitrienko, Parniak, "Carboxanilide derivative nonnucleoside inhibitors of HIV-1 reverse transcriptase interact with different
30 mechanistic forms of the enzyme," *Biochem.*, 34:4036-4042, 1995b.

- Follis, Trahey, LaCasse, Nunberg, "Continued utilization of CCR5 Coreceptor by a newly derived T-cell line-adapted isolate of Human Immunodeficiency Virus Type 1," *J. Virol.*, 72:7603-7608, 1998.
- Furman *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 83:8333-8337, 1986.
- 5 Gibbons *et al.*, "Thy/Liv-SCId-Hu mice implanted with human intestine: an in vivo model for investigation of mucosal transmission of HIV," *AIDS Res Hum Retroviruses*, 13(17):1453-1460, 1997.
- Goldman, Nunberg, O'Brien, Quintero, Schleif, Freund, Gaul, Saari, Wai, Anderson, Hupe, Emini, Stern, *Proc. Natl. Acad. Sci. U.S.A.*, 88:6863-6867, 1991.
- 10 Grob, Wu, Cohen, Ingraham, Shih, Hargrave, McTague, Merluzzi, *AIDS Res. Hum. Retroviruses*, 8:145-152, 1992.
- Hardy, "The Human Immunodeficiency Virus," *Medical Clinics of North America*, 80:1239-1261, 1996.
- Hargrave *et al.*, *J. of Medicinal Chemistry*, 34:2231-2241, 1991.
- 15 Haynes *et al.*, *Science* 271:324-328, 1996.
- Ho, Neumann, Perelson, *et al.*, "Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection," *Nature*, 373:123, 1995.
- Hu D J, Dondero TJ, Rayfield MA, *et al.*, The emerging genetic diversity of HIV: The importance of global surveillance for diagnostics, research, and prevention.
- 20 JAMA 275:210, 1996.
- Hwang, Boyle, Lyerly, *et al.*, "Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1," *Science*, 257:535, 1992.
- Johnson *et al.*, "Infectivity assay" In Aldovini a. Walker B.D., eds. *Techniques in HIV research*. New York: Stockton Press:71-76, 1990.
- 25 Johnson, Montefiori, Goldstein, Hamm, Zhou, Kitov, *et al.*, "Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge," *Proc. Natl Acad. Sci. USA*, 89:2175-9, 1992a.
- 30 Johnston, *Hospital Practice*, 32(5):125-8, 131-40, 1997.

Kindt *et al.*, "Animal models for acquired immunodeficiency syndrome," In Advances in Immunology, vol 52. Academic Press, Inc., New York, NY, 425-474, 1992.

Kleim *et al.*, *Virology*, 231(1):112-118, 1997.

Knight, "Bone-marrow-derived dendritic cells and the pathogenesis of AIDS," *AIDS (Lond.)*, 10:807-817, 1996.

LaCasse, Follis, Trahey, Scarborough, Littman, Nunberg, "Fusion-competent vaccines: broad neutralization of primary isolates of HIV," *Science*, 283:357-362, 1999.

LaCasse, Follis, Moudgil, Trahey, Binley, Planelles, Zolla-Pazner, Nunberg, "Coreceptor Utilization by Human Immunodeficiency Virus Type 1 is not a primary determinant of neutralization sensitivity," *J. Virol.* 72:2491-2495, 1998.

Le Grand, Vogt, Vaslin, Roques, Theodoro, Aubertin, *et al.*, "Specific and non-specific immunity and protection of macaques against SIV infection," *Vaccine*, 10:873-9, 1992.

McCune *et al.*, *Science*, 241:1632-1639, 1988.

Merluzzi, Hargrave, Labadia, Grozinger, Skoog, Wu, Shih, Eckner, Hattox, Adams, Rosethal, Faanes, Echner, Koup, Sullivan, *Sci.*, 20:1411-1413, 1990.

Montefiori and Moore, "Magic of the Occult?" *Science*, 283:336-337, 1999.

Mosier *et al.*, *Nature*, 335:256-259, 1988.

Murphey-Corb, Martin, Davison-Fairburn, Montelaro, Miller, West, *et al.*, "A formalin-inactivated whole SIV vaccine confers protection in macaques," *Science*, 246:1293-7, 1989.

Musey, Hughes, Schacker, Shea, Corey, McElrath, "Cytotoxic T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection," *N. Eng. J. Med.*, 337(18):1267-1274, 1997.

Oldstone, "HIV versus cytotoxic T lymphocytes - the war being lost," *N. Eng. J. Med.*, 337:1306-1308, 1997.

Osterhaus, de Vries, Morein, Akerblom, Heeney, "Comparison of protection afforded by whole virus ISCOM versus MDP adjuvanated Formalin-inactivated SIV

- vaccines from i.v. cellfree or cell-associated homologous challenge," *AIDS Res. Hum. Retrovir.*, 8:1507-10, 1992.
- Piatak Jr, Sang, Yang, *et al.*, "High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR," *Science*, 259:1749, 1993.
- 5 Putkonen, Thorstensson, Cranage, Nilsson, Ghavamzadeh, Albert, *et al.*, "A formalin inactivated whole SIVmac vaccine in Ribi adjuvant protects against homologous and heterologous SIV challenge," *J. Med. Primatol.*, 21:108-12, 1992.
- 10 Putkonen, Thorstensson, Walther, Albert, Akerblom, Granquist, *et al.*, "Vaccine protection against HIV-2 infection in cynomolgus monkeys," *AIDS Res. Hum. Retrovir.*, 7:271-7, 1991.
- Rosenberg *et al.*, *Science* 278:1447-1450, 1997.
- Sabin, "Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry," *Proc. Natl. Acad. Sci. USA*, 89:8852-5, 1992.
- 15 Schultz, "Changing paradigms for an HIV vaccine," Novel Strategies in the Design and Production of Vaccines Cohen and Shafferman (Eds.) New York, NY, *Advances in Experimental Medicine and Biology*, 397:79-90, 1996.
- Stanley *et al.*, *N. Engl. J. Med.*, 334:1222, 1996.
- 20 Stott and Schild, *Journal of Antimicrobial Chemotherapy* 37, Suppl. B, 185-198, 1996.
- Stott, Chan, Mills, Page, Taffs, Cranage, *et al.*, "Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by a whole fixed cell vaccine," *Lancet*, 336:1538-41, 1990.
- 25 Stott, Kitchin, Page, Flanagan, Taffs, Chan, *et al.*, "Anti-cell antibody in macaques," *Nature*, 353:393, 1991.
- Sutjipto, Pedersen, Miller, Gardner, Hanson, Gettie, *et al.*, "Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously
- 30 exposed animals," *J. Virol.*, 64:2290-7, 1990.

Warren and Dolatshahi, "First updated and revised survey of worldwide HIV and SIV vaccine challenge studies in non-human primates: progress in first and second order studies," *J. Med. Primatol.*, 22:203-35, 1993.

Weissman *et al.*, *J. Exp. Med.*, 183:687, 1996.

5 Yang *et al.*, *Journal of AIDS and Human Retrovirology*, 17:27-34, 1998.

Zhang *et al.*, "Reverse transcription takes place within extracellular HIV-1 virions: potential biological significance," *AIDS Res. Hum. Retroviruses* 9:1287-1296, 1993.

10 Zhang, Dornadula, Pomerantz, "Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenvironments: an important stage for viral infection of nondividing cells," *J. Virol.*, 70:2809-2824, 1996.

WHAT IS CLAIMED IS:

1. A composition comprising an HIV particle comprising inactivated reverse transcriptase.

5

2. The composition of claim 1, further comprising a pharmaceutically-acceptable excipient.

10

3. The composition of claim 1, wherein said HIV particle is HIV-1.

4. The composition of claim 3, wherein said HIV-1 is Group M or Group O.

15

5. The composition of claim 4, wherein said Group M are selected from the group consisting of clade A, clade B, clade C, clade D, clade E, clade F, clade G, clade H, and clade I.

20

6. The composition of claim 4, wherein said Group M particles are clade B particles.

25

7. The composition of claim 1, wherein said reverse transcriptase has been inactivated via binding said reverse transcriptase with one or more compounds that binds said reverse transcriptase and irradiating said HIV particles comprising reverse transcriptase bound by said one or more compounds with UV light.

30

8. The composition of claim 7, wherein said binding of said reverse transcriptase with one or more compounds is irreversible.

9. The composition of claim 7, wherein said compounds are azido-labeled compounds.

10. The composition of claim 9, wherein said azido-labeled compound is azido dipyrodiazepinona or azido-UC781™.

11. The composition of claim 10, wherein said azido-labeled compound is azido-UC781™.

12. The composition of claim 7, wherein said inactivation comprises contacting said HIV particle with an effective amount of UC781™.

13. A method of invoking an immune response in an animal which comprises administering to said animal a composition comprising a pharmaceutically-acceptable excipient and an HIV particle comprising inactivated reverse transcriptase.

14. The method of claim 13, wherein said immune response is a cellular response

15. The method of claim 13, wherein said immune response is a humoral response.

16. The method of claim 15, wherein said cellular response comprises CD8+ T cells.

5 17. The method of claim 15, wherein said cellular response comprises CD4+ T cells.

10 18. The method of claim 13, wherein said animal is a mammal.

19. The method of claim 18, wherein said mammal is a PBL-SCID mouse or a SCID-hu mouse.

15 20. The method of claim 18, wherein said mammal is human.

20 21. The method of claim 13, wherein said animal is HIV-negative.

22. The method of claim 13, wherein said animal is HIV-positive.

25 23. A method of delaying the onset of AIDS in an animal exposed to infectious HIV which comprises administering to said animal one or more inoculations of the composition of claim 1.

30 24. The method of claim 23, wherein said animal is a mammal.

25. The method of claim 24, wherein said mammal is a PBL-SCID mouse or a SCID-hu mouse.

5

26. The method of claim 24, wherein said mammal is a human.

10

27. The method of claim 23, wherein said animal is HIV-negative at the time of administration of the composition of claim 1.

15

28. The method of claim 23, wherein said animal is HIV-positive at the time of administration of the composition of claim 1.

29. A method of making an HIV particle comprising an inactive reverse transcriptase comprising:

20

- a) obtaining an HIV particle comprising reverse transcriptase;
- b) obtaining a compound capable of binding reverse transcriptase;
- c) contacting said HIV particle with said compound such that said compound binds said reverse transcriptase;
- d) irradiating said HIV particle

25

30. The method of claim 29, wherein said HIV particle is HIV-1.

31. The method of claim 30, wherein said HIV-1 is Group M or Group O.

30

32. The method of claim 31, wherein said Group M are selected from the group consisting of clade A, clade B, clade C, clade D, clade E, clade F, clade G, clade H, and clade I.

5

33. The method of claim 31, wherein said Group M particles are clade B particles.

10

34. The method of claim 29, wherein said compound is an azido-labeled compound.

15

35. The method of claim 34, wherein said azido-labeled compound is azido dipyrodiazepinona or azido-UC781™.

20

36. The composition of claim 35, wherein said azido-labeled compound is azido-UC781™.

25

37. A method of preparing a composition comprising:

a) obtaining an HIV particle comprising an inactive reverse transcriptase comprising:

i) obtaining an HIV particle comprising reverse transcriptase;

ii) obtaining a compound capable of binding reverse transcriptase;

iii) contacting said HIV particle with said compound such that said compound binds said reverse transcriptase; and

iv) irradiating said HIV particle;

b) combining said particle into a pharmaceutically acceptable excipient.

30




FIG. 1

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 99/03217

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N7/06 A61K39/21

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BORKOW G ET AL.: "Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocaboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase" J. VIROL., vol. 71, no. 4, April 1997, pages 3023-30, XP002105761 cited in the application see page 3023, left-hand column, line 6-9 see page 3023, right-hand column, line 9-24 see page 3024, left-hand column, paragraph 3 see page 3027, right-hand column, line 1-43 see page 3028, right-hand column, line 1-2	1-6, 13-28
Y	-/--	7-12, 29-37

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 June 1999

Date of mailing of the international search report

06/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

COVONE, M

INTERNATIONAL SEARCH REPORT

Inter: onal Application No
PCT/US 99/03217

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p style="text-align: center;">---</p> <p>FLETCHER RS ET AL.: "Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme" BIOCHEMISTRY, vol. 34, no. 13, 4 April 1995, pages 4346-53, XP002105762 cited in the application see page 4347, right-hand column, line 20-57 see page 4349, right-hand column, line 7 - page 4350, left-hand column, line 14</p>	7-12, 29-37
X	<p style="text-align: center;">---</p> <p>BUCKHEIT RW ET AL.: "Efficacy, pharmacokinetics and in vivo anti-HIV activity of the highly potent oxathiin carboxanilide analog, UC781" JOURNAL OF MOLECULAR MEDICINE, vol. 75, no. 7, 1997, pages b212-b213, XP002105763 see the whole document</p>	1-6, 13-28
A	<p style="text-align: center;">---</p> <p>SUHADOLNIK R J: "Photolabeling of the enzymes of the 2-5A synthetase/RNase L/p68 kinase antiviral systems with azido probes." PROGRESS IN MOLECULAR AND SUBCELLULAR BIOLOGY, (1994) 14 260-75. REF: 77 JOURNAL CODE: BYS. ISSN: 0079-6484., XP002105764 United States see page 270 - page 271</p> <p style="text-align: center;">-----</p>	1-37

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 03217

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13-28
because they relate to subject matter not required to be searched by this Authority, namely:
See FURTHER INFORMATION SHEET PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99 03217

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 13-28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Claims Nos.: 13-28

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy